Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
J Esquivel, R Sticca, P Sugarbaker, E Levine, T D Yan, R Alexander, D Baratti, D Bartlett, R Barone, P Barrios, S Bieligk, P Bretcha-Boix, C K Chang, F Chu, Q Chu, S Daniel, E de Bree, M Deraco, L Dominguez-Parra, D Elias, R Flynn, J Foster, A Garofalo, F N Gilly, O Glehen, A Gomez-Portilla, L Gonzalez-Bayon, S Gonzalez-Moreno, M Goodman, V Gushchin, N Hanna, J Hartmann, L Harrison, R Hoefer, J Kane, D Kecmanovic, S Kelley, J Kuhn, J Lamont, J Lange, B Li, B Loggie, H Mahteme, G Mann, R Martin, R A Misih, B Moran, D Morris, L Onate-Ocana, N Petrelli, G Philippe, J Pingpank, A Pitroff, P Piso, M Quinones, L Riley, L Rutstein, S Saha, S Alrawi, A Sardi, S Schneebaum, P Shen, D Shibata, J Spellman, A Stojadinovic, J Stewart, J Torres-Melero, T Tuttle, V Verwaal, J Villar, N Wilkinson, R Younan, H Zeh, F Zoetmulder, G Sebbag
No abstract text is available yet for this article.
January 2007: Annals of Surgical Oncology
#2
JOURNAL ARTICLE
Carmel Jacobs, Ian D Graham, Julie Makarski, Michaël Chassé, Dean Fergusson, Brian Hutton, Mark Clemons
BACKGROUND: Consensus statements and clinical practice guidelines are widely available for enhancing the care of cancer patients. Despite subtle differences in their definition and purpose, these terms are often used interchangeably. We systematically assessed the methodological quality of consensus statements and clinical practice guidelines published in three commonly read, geographically diverse, cancer-specific journals. Methods Consensus statements and clinical practice guidelines published between January 2005 and September 2013 in Current Oncology, European Journal of Cancer and Journal of Clinical Oncology were evaluated...
2014: PloS One
#3
JOURNAL ARTICLE
P J Karanicolas, P Metrakos, K Chan, T Asmis, E Chen, T P Kingham, N Kemeny, G Porter, R C Fields, J Pingpank, E Dixon, A Wei, S Cleary, G Zogopoulos, C Dey, M D'Angelica, Y Fong, S Dowden, Y J Ko
Despite significant improvements in systemic therapy for patients with colorectal liver metastases (crlms), response rates in the first-line setting are not optimal, and response rates in the second-line setting remain disappointing. Hepatic arterial infusion pump (haip) chemotherapy has been extensively studied in patients with crlms, but it remains infrequently used. We convened an expert panel to discuss the role of haip in the contemporary management of patients with crlm. Using a consensus process, we developed these statements: haip chemotherapy should be given in combination with systemic chemotherapy...
February 2014: Current Oncology
#4
REVIEW
Song Cheol Kim, Young Hoon Kim, Kwang Min Park, Young Ju Lee
Pancreatic cancer patients have an extremely poor survival prognosis, and surgical resection remains the only curative treatment. Greater experience in pancreatic surgery and developments in surgical techniques have reduced surgical mortality and morbidity rates. It has been suggested that experienced pancreaticoduodenectomy centers should have mortality rates of less than 5% and major complication rates of less than 40%. Surgical resection followed by combined adjuvant therapy is currently the standard treatment for resectable pancreas cancer...
June 2012: Current Drug Targets
#5
REVIEW
Kathleen K Christians, Alysandra Lal, Sam Pappas, Edward Quebbeman, Douglas B Evans
The American Hepato-Pancreatico-Biliary Association and Society of Surgical Oncology published a consensus statement in 2009 on the subject of vein resection and reconstruction during pancreaticoduodenectomy (PD), and concluded that PD with vein resection and reconstruction is a viable option for treatment of some pancreatic adenocarcinomas. This article describes the current approaches and recent advances in the management, staging, and surgical techniques regarding portal vein resection. With proper patient selection, a detailed understanding of the anatomy of the root of mesentery, and adequate surgeon experience, vascular resection and reconstruction can be performed safely and does not impact survival duration...
April 2010: Surgical Clinics of North America
#6
REVIEW
José G Guillem, William C Wood, Jeffrey F Moley, Andrew Berchuck, Beth Y Karlan, David G Mutch, Robert F Gagel, Jeffrey Weitzel, Monica Morrow, Barbara L Weber, Francis Giardiello, Miguel A Rodriguez-Bigas, James Church, Stephen Gruber, Kenneth Offit
BACKGROUND: A significant portion of cancers are accounted for by a heritable component, which has increasingly been linked to mutations in specific genes. Clinical interventions have been formulated for mutation carriers within affected families. The primary interventions for mutation carriers of highly penetrant syndromes are surgical. METHODS: The American Society of Clinical Oncology and the Society of Surgical Oncology formed a task force charged with presenting an educational symposium on surgical management of hereditary cancer syndromes at annual society meetings, and this resulted in a position paper on this topic...
October 2006: Annals of Surgical Oncology
#7
REVIEW
José G Guillem, William C Wood, Jeffrey F Moley, Andrew Berchuck, Beth Y Karlan, David G Mutch, Robert F Gagel, Jeffrey Weitzel, Monica Morrow, Barbara L Weber, Francis Giardiello, Miguel A Rodriguez-Bigas, James Church, Stephen Gruber, Kenneth Offit
Although the etiology of solid cancers is multifactorial, with environmental and genetic factors playing a variable role, a significant portion of the burden of cancer is accounted for by a heritable component. Increasingly, the heritable component of cancer predispositions has been linked to mutations in specific genes, and clinical interventions have been formulated for mutation carriers within affected families. The primary interventions for mutations carriers for highly penetrant syndromes such as multiple endocrine neoplasias, familial adenomatous polyposis, hereditary nonpolyposis colon cancer, and hereditary breast and ovarian cancer syndromes are primarily surgical...
October 1, 2006: Journal of Clinical Oncology
#8
REVIEW
Donald Poon, Benjamin O Anderson, Li-Tzong Chen, Koichi Tanaka, Wan Yee Lau, Eric Van Cutsem, Harjit Singh, Wan Cheng Chow, London Lucien Ooi, Pierce Chow, Maung Win Khin, Wen Hsin Koo
Asia has a disproportionately large share of the world's hepatocellular carcinoma (HCC), mainly because of the endemic status of chronic hepatitis B and C viruses, which leads to liver cirrhosis and an increased risk of HCC. This etiological factor presents important opportunities for prevention, early detection, diagnosis, and treatment of HCC. This consensus statement reviews the available medical evidence for management of HCC in Asia, and gives treatment recommendations that are adapted to resource availability in this diverse region with disparate health-care delivery systems...
November 2009: Lancet Oncology
#9
COMPARATIVE STUDY
Martin E Blackstein, Jean-Yves Blay, Christopher Corless, David K Driman, Robert Riddell, Denis Soulières, Carol J Swallow, Shailendra Verma
In the multidisciplinary management of gastrointestinal stromal tumours (GISTs), there is a need to coordinate the efforts of pathology, radiology, surgery and oncology. Surgery is the mainstay for resectable nonmetastatic GISTs, but virtually all GISTs are associated with a risk of metastasis. Imatinib 400 mg/day with or without surgery is the recommended first-line treatment for recurrent or metastatic GIST; a higher dose may be considered in patients who progress, develop secondary resistance or present with specific genotypic characteristics...
March 2006: Canadian Journal of Gastroenterology
#10
JOURNAL ARTICLE
Josep M Borras, Tit Albreht, Riccardo Audisio, Erik Briers, Paolo Casali, Hélène Esperou, Birgitte Grube, Marc Hamoir, Geoffrey Henning, Joan Kelly, Susan Knox, Maria Nabal, Marco Pierotti, Claudio Lombardo, Wim van Harten, Graeme Poston, Joan Prades, Milena Sant, Luzia Travado, Vincenzo Valentini, Cornelis van de Velde, Saskia van den Bogaert, Marc van den Bulcke, Elke van Hoof, Ingrid van den Neucker, Robin Wilson
BACKGROUND: Cancer care is undergoing an important paradigm shift from a disease-focused management to a patient-centred approach, in which increasingly more attention is paid to psychosocial aspects, quality of life, patients' rights and empowerment and survivorship. In this context, multidisciplinary teams emerge as a practical necessity for optimal coordination among health professionals and clear communication with patients. The European Partnership for Action Against Cancer (EPAAC), an initiative launched by the European Commission in 2009, addressed the multidisciplinary care from a policy perspective in order to define the core elements that all tumour-based multidisciplinary teams (MDTs) should include...
February 2014: European Journal of Cancer
#11
JOURNAL ARTICLE
Roderich E Schwarz, Ghassan K Abou-Alfa, Jeffrey F Geschwind, Sunil Krishnan, Riad Salem, Alan P Venook
Although surgical resection and liver transplantation are the only treatment modalities that enable prolonged survival in patients with hepatocellular carcinoma (HCC), the majority of HCC patients presents with advanced disease and do not undergo resective or ablative therapy. Transarterial chemoembolization (TACE) is indicated in intermediate/advanced stage unresectable HCC even in the setting of portal vein involvement (excluding main portal vein). Sorafenib has been shown to improve survival of patients with advanced HCC in two controlled randomized trials...
June 2010: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
#12
JOURNAL ARTICLE
Joseph F Buell, Daniel Cherqui, David A Geller, Nicholas O'Rourke, David Iannitti, Ibrahim Dagher, Alan J Koffron, Mark Thomas, Brice Gayet, Ho Seong Han, Go Wakabayashi, Giulio Belli, Hironori Kaneko, Chen-Guo Ker, Olivier Scatton, Alexis Laurent, Eddie K Abdalla, Prosanto Chaudhury, Erik Dutson, Clark Gamblin, Michael D'Angelica, David Nagorney, Giuliano Testa, Daniel Labow, Derrik Manas, Ronnie T Poon, Heidi Nelson, Robert Martin, Bryan Clary, Wright C Pinson, John Martinie, Jean-Nicolas Vauthey, Robert Goldstein, Sasan Roayaie, David Barlet, Joseph Espat, Michael Abecassis, Myrddin Rees, Yuman Fong, Kelly M McMasters, Christoph Broelsch, Ron Busuttil, Jacques Belghiti, Steven Strasberg, Ravi S Chari
OBJECTIVE: To summarize the current world position on laparoscopic liver surgery. SUMMARY BACKGROUND DATA: Multiple series have reported on the safety and efficacy of laparoscopic liver surgery. Small and medium sized procedures have become commonplace in many centers, while major laparoscopic liver resections have been performed with efficacy and safety equaling open surgery in highly specialized centers. Although the field has begun to expand rapidly, no consensus meeting has been convened to discuss the evolving field of laparoscopic liver surgery...
November 2009: Annals of Surgery
#13
REVIEW
A Stanley, A Young
Recent data suggest that patients with a malignancy have a seven-fold increased risk for venous thromboembolism (VTE) compared with those without cancer, suggesting that these patients may benefit from thromboprophylaxis. Mechanisms for the prevention of thromboembolism can be divided into two broad categories: mechanical and pharmacological. Although generally used in combination with pharmacotherapy, little evidence exists for the efficacy of mechanical modalities either in the broader population of patients at risk for VTE or for patients with cancer specifically...
April 13, 2010: British Journal of Cancer
#14
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: The management of primary rectal cancer beyond total mesorectal excision planes (PRC-bTME) and recurrent rectal cancer (RRC) is challenging. There is global variation in standards and no guidelines exist. To achieve cure most patients require extended, multivisceral, exenterative surgery, beyond conventional total mesorectal excision planes. The aim of the Beyond TME Group was to achieve consensus on the definitions and principles of management, and to identify areas of research priority...
July 2013: British Journal of Surgery
#15
JOURNAL ARTICLE
Jean-Nicolas Vauthey, Elijah Dixon, Eddie K Abdalla, W Scott Helton, Timothy M Pawlik, Bachir Taouli, Antoine Brouquet, Reid B Adams
Staging of hepatocellular carcinoma (HCC) is complex and relies on multiple factors including tumor extent and hepatic function. No single staging system is applicable to all patients with HCC. The staging of the American Joint Committee on Cancer / International Union for Cancer Control should be used to predict outcome following resection or liver transplantation. The Barcelona Clinic Liver Cancer scheme is appropriate in patients with advanced HCC not candidate for surgery. Dual phase computed tomography or magnetic resonance imaging can be used for pretreatment assessment of tumor extent but the accuracy of these methods remains poor to characterize < 1 cm lesions...
June 2010: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
#16
REVIEW
William Jarnagin, William C Chapman, Steven Curley, Michael D'Angelica, Charles Rosen, Elijah Dixon, David Nagorney
As the number of effective treatment options has increased, the management of patients with hepatocellular carcinoma has become complex. The most appropriate therapy depends largely on the functional status of the underlying liver. In patients with advanced cirrhosis and tumor extent within the Milan criteria, liver transplantation is clearly the best option, as this therapy treats the cancer along with the underlying hepatic parenchymal disease. As the results of transplantation has become established in patients with limited disease, investigation has increasingly focused on downstaging patients with disease outside of Milan criteria and defining the upper limits of transplantable tumors...
June 2010: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
#17
JOURNAL ARTICLE
Reid B Adams, Thomas A Aloia, Evelyne Loyer, Timothy M Pawlik, Bachir Taouli, Jean-Nicolas Vauthey
Hepatic resection offers a chance of a cure in selected patients with colorectal liver metastases (CLM). To achieve adequate patient selection and curative surgery, (i) precise assessment of the extent of disease, (ii) sensitive criteria for chemotherapy effect, (iii) adequate decision making in surgical indication and (iv) an optimal surgical approach for pre-treated tumours are required. For assessment of the extent of the disease, contrast-enhanced computed tomography (CT) and/or magnetic resonance imaging (MRI) with gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) is recommended depending on the local expertise and availability...
February 2013: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
